PPP2R2A and metastatic melanoma: Most melanoma cell lines included in the CRISPR‐Cas9 screens carried the BRAF mutation, but screen data suggested that some NRAS‐mutant melanoma cells might also be sensitive to inactivation of DUSP4 and PPP2R2A. Targeting these proteins may provide an alternative approach to treatment of metastatic melanoma, particularly after relapse from immunotherapy or targeted therapy.